WO2010130260A3 - Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Google Patents

Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide Download PDF

Info

Publication number
WO2010130260A3
WO2010130260A3 PCT/DK2010/050101 DK2010050101W WO2010130260A3 WO 2010130260 A3 WO2010130260 A3 WO 2010130260A3 DK 2010050101 W DK2010050101 W DK 2010050101W WO 2010130260 A3 WO2010130260 A3 WO 2010130260A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl
morpholin
phenyl
butyramide
stable forms
Prior art date
Application number
PCT/DK2010/050101
Other languages
French (fr)
Other versions
WO2010130260A2 (en
WO2010130260A9 (en
Inventor
Svend Treppendahl
Karin Liltorp
Heidi Lopez De Diego
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010130260(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ596738A priority Critical patent/NZ596738A/en
Priority to MA34435A priority patent/MA33351B1/en
Priority to EA201171381A priority patent/EA201171381A1/en
Priority to MX2011011885A priority patent/MX2011011885A/en
Priority to BRPI1013930A priority patent/BRPI1013930A2/en
Priority to JP2012510116A priority patent/JP2012526152A/en
Priority to CN2010800321765A priority patent/CN102459208A/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to CA2761383A priority patent/CA2761383A1/en
Priority to AU2010246724A priority patent/AU2010246724B2/en
Priority to EP10719726A priority patent/EP2430008A2/en
Priority to SG2011082492A priority patent/SG175968A1/en
Publication of WO2010130260A2 publication Critical patent/WO2010130260A2/en
Publication of WO2010130260A3 publication Critical patent/WO2010130260A3/en
Priority to IL216148A priority patent/IL216148A0/en
Priority to TNP2011000557A priority patent/TN2011000557A1/en
Priority to ZA2011/08112A priority patent/ZA201108112B/en
Publication of WO2010130260A9 publication Critical patent/WO2010130260A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramideare provided together with a process for the manufacture of said compound.
PCT/DK2010/050101 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide WO2010130260A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2761383A CA2761383A1 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
AU2010246724A AU2010246724B2 (en) 2009-05-11 2010-05-11 Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramide
MA34435A MA33351B1 (en) 2009-05-11 2010-05-11 Stable form n (2.6 dimethyl 4-morpholine 4-phenyl)
EP10719726A EP2430008A2 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
BRPI1013930A BRPI1013930A2 (en) 2009-05-11 2010-05-11 "compound, pharmaceutical composition, method for treating a disease, use of a compound, and process for making a compound."
JP2012510116A JP2012526152A (en) 2009-05-11 2010-05-11 Stable form of N- (2,6-dimethyl-4-morpholin-4-yl-phenyl) -3,3-dimethyl-butyramide
CN2010800321765A CN102459208A (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
NZ596738A NZ596738A (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
SG2011082492A SG175968A1 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
EA201171381A EA201171381A1 (en) 2009-05-11 2010-05-11 STABLE FORMS N- (2,6-DIMETHYL-4-MORFOLIN-4-ILPHENYL) -3,3-DIMETYLBUTYRAMIDE
MX2011011885A MX2011011885A (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dime thyl-butyramide.
IL216148A IL216148A0 (en) 2009-05-11 2011-11-03 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
TNP2011000557A TN2011000557A1 (en) 2009-05-11 2011-11-04 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
ZA2011/08112A ZA201108112B (en) 2009-05-11 2011-11-04 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11
DKPA200900597 2009-11-05

Publications (3)

Publication Number Publication Date
WO2010130260A2 WO2010130260A2 (en) 2010-11-18
WO2010130260A3 true WO2010130260A3 (en) 2011-06-16
WO2010130260A9 WO2010130260A9 (en) 2012-10-18

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2010/050101 WO2010130260A2 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Country Status (23)

Country Link
EP (1) EP2430008A2 (en)
JP (1) JP2012526152A (en)
KR (1) KR20120022934A (en)
CN (1) CN102459208A (en)
AR (1) AR076556A1 (en)
AU (1) AU2010246724B2 (en)
BR (1) BRPI1013930A2 (en)
CA (1) CA2761383A1 (en)
CL (1) CL2011002814A1 (en)
CO (1) CO6460741A2 (en)
CR (1) CR20110590A (en)
DO (1) DOP2011000351A (en)
EA (1) EA201171381A1 (en)
GE (1) GEP20146006B (en)
IL (1) IL216148A0 (en)
MA (1) MA33351B1 (en)
MX (1) MX2011011885A (en)
NZ (1) NZ596738A (en)
SG (1) SG175968A1 (en)
TN (1) TN2011000557A1 (en)
TW (1) TW201041857A (en)
WO (1) WO2010130260A2 (en)
ZA (1) ZA201108112B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087754A1 (en) * 2004-03-12 2005-09-22 H. Lundbeck A/S Substituted morpholine and thiomorpholine derivatives
WO2008024398A2 (en) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087754A1 (en) * 2004-03-12 2005-09-22 H. Lundbeck A/S Substituted morpholine and thiomorpholine derivatives
WO2008024398A2 (en) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/3-540-69178-2_5, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954 *
SAMEER URGAONKAR ET AL: "Palladium/Proazaphosphatrane-Catalyzed Amination of Aryl Halides Possessing a Phenol, Alcohol, Acetanilide, Amide or an Enolizable Ketone Functional Group: Efficacy of Lithium Bis(trimethylsilyl)amide as the Base", ADVANCED SYNTHESIS & CATALYSIS, vol. 346, no. 6, 1 May 2004 (2004-05-01), pages 611 - 616, XP055034677, ISSN: 1615-4150, DOI: 10.1002/adsc.200404005 *

Also Published As

Publication number Publication date
WO2010130260A2 (en) 2010-11-18
MX2011011885A (en) 2011-12-06
AU2010246724A1 (en) 2011-12-08
BRPI1013930A2 (en) 2019-09-24
SG175968A1 (en) 2011-12-29
WO2010130260A9 (en) 2012-10-18
GEP20146006B (en) 2014-01-10
CO6460741A2 (en) 2012-06-15
DOP2011000351A (en) 2012-01-31
MA33351B1 (en) 2012-06-01
EP2430008A2 (en) 2012-03-21
JP2012526152A (en) 2012-10-25
TN2011000557A1 (en) 2013-05-24
AU2010246724B2 (en) 2013-03-21
KR20120022934A (en) 2012-03-12
CA2761383A1 (en) 2010-11-18
NZ596738A (en) 2013-04-26
AR076556A1 (en) 2011-06-22
TW201041857A (en) 2010-12-01
CR20110590A (en) 2012-02-22
ZA201108112B (en) 2013-01-30
CN102459208A (en) 2012-05-16
EA201171381A1 (en) 2012-05-30
CL2011002814A1 (en) 2012-04-13
IL216148A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
WO2009048101A1 (en) Amide compound
PL1993985T3 (en) Process for the preparation of 1,2-propanediol
WO2009036281A3 (en) Bortezomib and process for producing same
EP2361902A4 (en) 4,6-diaminonicotinamide compound
WO2009012734A3 (en) New salts of bazedoxifene
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
EP2227690A4 (en) The micro-chamber plate, manufacturing method thereof
HUE044749T2 (en) Improved promoter, and a production method for l-lysine using the same
MX285136B (en) Polyetheramine production method.
ZA201004118B (en) Process for the production of 1,2-propanediol
WO2011134724A3 (en) Method for preparing ritodrine hydrochloride
WO2009149344A3 (en) Solid states of aliskiren free base
EG25292A (en) Process for the production of anilines.
WO2011018771A3 (en) Process for the preparation of valganciclovir hydrochloride
WO2009114685A3 (en) O-desmethylvenlafaxine salts
WO2009122429A3 (en) Crystalline oxybutynin and process for preparing the same
EP2330212A4 (en) Novel compound ceramidastin, process for production thereof, and use thereof
WO2010130260A3 (en) Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
WO2009027766A3 (en) New crystalline solid forms of o-desvenlafaxine base
BR112012004523A2 (en) Process for the preparation of (1s, 4r) -2-oxa-3-azabicyclo [2.2.1] hept-5-enos
WO2010004386A3 (en) Amorphous bupropion hydrobromide and preparation thereof
TWI366559B (en) Process for the production of anilines
WO2011159740A3 (en) Methods for manufacturing tetranor-prostaglandin d, j, e, a and f metabolites
EP1915380A4 (en) Process for the preparation of n,n´- disubstituted oxabispidines
PL382315A1 (en) Method for the manufacture of S-(-)-6-methoxy-1, 2, 3, 4-tetrahydro-2-naphtol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080032176.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719726

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2761383

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/011885

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012510116

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20117026958

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11153611

Country of ref document: CO

Ref document number: 8279/CHENP/2011

Country of ref document: IN

Ref document number: CR2011-000590

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2010246724

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010719726

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 596738

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2010246724

Country of ref document: AU

Date of ref document: 20100511

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12498

Country of ref document: GE

Ref document number: 201171381

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1013930

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 13061

Country of ref document: GE

ENP Entry into the national phase

Ref document number: PI1013930

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111110